Study To Assess The Impact Of Hepatic Impairment On The Safety, Tolerability And Pharmacokinetics Of Single-Dose 200 Mg Of PF-868554

HEPATITIS C (HCV) Clinical Trial

Official title:
An Open Label Study, To Evaluate The Pharmacokinetics, Safety And Toleration Of A Single Oral Dose Of Pf-00868554 In Subjects With Hepatic Impairment To Subjects With Normal Hepatic Function

Status Completed

Clinical Trial Summary

The metabolism of PF-00868554 is primarily mediated by CYP3A, and it is anticipated that hepatic impairment will modify PF-00868554 plasma concentrations. Hence, it is important to determine the impact of varying degrees of hepatic impairment on the pharmacokinetics, safety and toleration of 200 mg PF-00868554 administered as a single-dose.

Clinical Trial Description

n/a

Study Design

Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

HEPATITIS C (HCV)

Clinical Trial Details

NCT number	NCT00651027
Study type	Interventional
Source	Pfizer
Contact
Status	Completed
Phase	Phase 1
Start date	February 2008
Completion date	September 2008

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02593162` - A Study of Faldaprevir, Ribavirin and TD-6450 in Participants With Genotype 4 Hepatitis C Virus Infection	Phase 2
Completed	`NCT01464827` - ABT-450 With Ritonavir and ABT-267 and/or ABT-333 With and Without Ribavirin in Genotype 1 Hepatitis C Virus Infected Patients	Phase 2
Completed	`NCT02716428` - A Study of Faldaprevir, TD-6450 and Other Antivirals in Participants With Genotype 1b Hepatitis C Virus Infection	Phase 2
Active, not recruiting	`NCT05657106` - Kentucky Outreach Service Kiosk (KyOSK): Reducing HIV, HCV, and Overdose Risk	N/A
Completed	`NCT02476617` - Ombitasvir/ABT-450 (Paritaprevir)/Ritonavir With Dasabuvir and Ribavirin (RBV) in Treatment Naive and Treatment Experienced Genotype 1a Hepatitis C Virus Infected Adults	Phase 3
Completed	`NCT02493855` - Ombitasvir/ABT-450/Ritonavir and Dasabuvir Therapy With Low Dose Ribavirin (RBV), Full Dose RBV or RBV Add-On in Treatment Naive Genotype 1a Hepatitis C Virus Infected Adults	Phase 2
Recruiting	`NCT05968573` - Persuasive Health Communication Intervention for HIV/HCV	N/A
Not yet recruiting	`NCT01750515` - Acupuncture as an Adjunctive Treatment for Hepatitis C Patients	N/A